clinical trial · NCT03681184
A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
Primary Hyperoxaluria Type 1 (PH1)PlaceboLumasiran
brief summary
The purpose of this study is to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).
started
Nov 27, 2018
primary completion
Nov 5, 2019
completion
Jan 12, 2024
last updated
Aug 12, 2024
official title
ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol